Volume 7, Issue 4 pp. 337-350

REVIEW

Open Access

Application value and challenge of traditional Chinese medicine carried by ZIF-8 in the therapy of ischemic stroke

Xiao-Xi Zhu,

Xiao-Xi Zhu

Key Laboratory of Molecular Biology, Guizhou Medical University, Guiyang, Guizhou, China

Search for more papers by this author

Dong-Fen Guo,

Dong-Fen Guo

Key Laboratory of Molecular Biology, Guizhou Medical University, Guiyang, Guizhou, China

Search for more papers by this author

Ming Chen,

Ming Chen

Key Laboratory of Molecular Biology, Guizhou Medical University, Guiyang, Guizhou, China

Search for more papers by this author

Xiao-Qiong An,

Xiao-Qiong An

Key Laboratory of Molecular Biology, Guizhou Medical University, Guiyang, Guizhou, China

Search for more papers by this author

Bi Wang,

Bi Wang

Key Laboratory of Molecular Biology, Guizhou Medical University, Guiyang, Guizhou, China

Search for more papers by this author

Wen-Feng Yu,

Corresponding Author

Wen-Feng Yu

[email protected]

Key Laboratory of Molecular Biology, Guizhou Medical University, Guiyang, Guizhou, China

Key Laboratory of Endemic and Minority Diseases, Education Ministry, Guizhou Medical University, Guiyang, Guizhou, China

School of Basic Medical Science, Guizhou Medical University, Guiyang, Guizhou, China

Correspondence Wen-Feng Yu, Key Laboratory of Endemic and Ethnic Diseases, Ministry of Education, College of Basic Medical Sciences, Guizhou Medical University, 9 Beijing Rd, Guiyang 550004, Guizhou, China.

Email: [email protected]

Search for more papers by this author

Xiao-Xi Zhu,

Xiao-Xi Zhu

Key Laboratory of Molecular Biology, Guizhou Medical University, Guiyang, Guizhou, China

Search for more papers by this author

Dong-Fen Guo,

Dong-Fen Guo

Key Laboratory of Molecular Biology, Guizhou Medical University, Guiyang, Guizhou, China

Search for more papers by this author

Ming Chen,

Ming Chen

Key Laboratory of Molecular Biology, Guizhou Medical University, Guiyang, Guizhou, China

Search for more papers by this author

Xiao-Qiong An,

Xiao-Qiong An

Key Laboratory of Molecular Biology, Guizhou Medical University, Guiyang, Guizhou, China

Search for more papers by this author

Bi Wang,

Bi Wang

Key Laboratory of Molecular Biology, Guizhou Medical University, Guiyang, Guizhou, China

Search for more papers by this author

Wen-Feng Yu,

Corresponding Author

Wen-Feng Yu

[email protected]

Key Laboratory of Molecular Biology, Guizhou Medical University, Guiyang, Guizhou, China

Key Laboratory of Endemic and Minority Diseases, Education Ministry, Guizhou Medical University, Guiyang, Guizhou, China

School of Basic Medical Science, Guizhou Medical University, Guiyang, Guizhou, China

Email: [email protected]

Search for more papers by this author

First published: Winter 2021

https://doi.org/10.1002/ibra.12007

Xiao-Xi Zhu and Dong-Fen Guo contributed equally to this study.

Share a link

Email
Wechat
Bluesky

Abstract

Stroke is a group of major diseases that cause death or disability in adults, with high incidence and lack of available therapeutic strategies. Although traditional Chinese medicine (TCM) has continuously achieved good effects in the therapy of stroke while there is still not convincing due to the limitation of blood–brain permeability, as well as the individual differences in usage and dosage. With the improvement of nanotechnology, TCM nanopreparation has gradually become a research hotspot in various fields due to its advantages in permeating the blood–brain barrier, targeting delivery, enhancing sustained-release drug delivery, changing the distribution in the body, and improving bioavailability. Zeolitic imidazolate framework-8 (ZIF-8) is an ideal nano-drug delivery system for adsorption, catalysis, and drug loading, which is a biocompatible metal–organic framework framed by 2-methylimidazole and zinc ions. At present, ZIF-8 was wildly used in the treatment of ischemic stroke. However, challenges remain persists for its clinical application, such as preparation technology, detection technology in vivo, targeting specificity, safety and stability, and so forth. Therefore, more efforts need to overcome the above problems to develop the application of TCM nanopreparations in the therapy of ischemia/reperfusion in the future.

1 INTRODUCTION

Stroke, as the second leading cause of death in the world, is receiving more and more focusses due to the multiple serious threats to human health such as high morbidity, high disability rate, high mortality rate, and high recurrence rate.¹ Meanwhile stroke gradually increased the global economic burden.^{2, 3} A total of 23%–65% of stroke patients with infectious complications resulted in unfavorable prognosis,⁴ and most of the surviving patients lose the ability to work to various degrees.⁵ Approximate 2.4 million new stroke cases are confirmed and appropriate 1.1 million people die from stroke each year in China, and the incidence of stroke tends to be younger.⁶ Statistically the incidence of cerebrovascular disease will increase by approximately 50% compared with that in 2010 in China by 2023.⁷

Stroke is mainly classified into ischemic stroke and hemorrhagic stroke with ischemic stroke incidence accounting for about 87% of all types of strokes. For prevention and treatment of stroke, institutions have respectively formulated and published multiple versions of the “Chinese Acute Ischemic Stroke Diagnosis and Treatment Guidelines,” including the Neurology Branch of the Chinese Medical Association, the Chinese Society of Traditional Chinese Medicine (TCM), and the Neurology Professional Committee of the Chinese Integrative Medicine Society,⁸ “Consensus on the Diagnosis and Treatment of Hemorrhage Transformation after Acute Cerebral Infarction in China 2019,”⁹ “Interpretation of Guidelines for Clinical Diagnosis and Treatment of Traditional Chinese Medicine”¹⁰ and “Diagnostic Standards of Integrated Traditional Chinese and Western Medicine for Cerebral Infarction and Cerebral Hemorrhage.”¹¹ These guidelines and standards have strongly promoted the development of TCM and integrated traditional Chinese and western medicine diagnosis use in treatment of cerebral stroke in China and played a positive role in standardizing the diagnosis and treatment of stroke in China.

Thrombolytic therapy is the conventional clinical treatment of ischemic stroke whereas there is the risk of causing bleeding reperfusion injury, and some patients cannot receive effective treatment in time due to its short optimal treatment window. In recent years, proper results of TCM use in ischemic stroke have been proven successful in animal experiments. However, it is blocked by the blood–brain barrier (BBB), making most of the drugs unable to exert their effects. The modified nanomaterials developed an excellent brain drug delivery system due to the great advantage in penetrating BBB.¹² TCM nanopreparations have gradually become a research hotspot in various fields due to their advantages in permeating BBB, targeting delivery, enhancing sustained-release drug delivery, changing the distribution in the body, and improving bioavailability.

Metal–organic frameworks (MOFs) are ideal materials for adsorption, catalysis, and drug loading due to their large specific surface area, easy modification of the surface, high porosity, easy adjustment of pore size, structural diversity, many unsaturated metal-binding sites, and good biocompatibility. Zeolite-type imidazole ester framework materials (ZIFs) are subclusters of MOFs, which are topological nanomaterials formed by self-assembly of transition metal atoms with organic imidazoles and their derivatives. Among them, zeolitic imidazolate framework-8 (ZIF-8) is a typical representative of ZIFs, and it is the first ZIFs material that have been found to have drug-carrying functions. ZIFs have mild synthesis conditions, high pH sensitivity, close interaction with biomolecules, hydrothermal stability, and chemical stability. ZIF-8 has the following advantages: high drug load, pH response characteristics, releasing high concentrations of drugs in certain acidic environments. ZIF-8 can also be designed to respond to other stimuli type drug delivery systems (such as light, heat, magnetic field, positioning, GSH, H₂O₂ stimulation, etc.) control the release of drugs in specific parts and reduce the toxic and side effects on normal tissues; the shell of ZIF-8 can protect the stability of biomolecules and improve biomolecules. The immobilized biomolecules are dispersed by ZIF-8, which can avoid the aggregation of biomolecules, improve the activity of biomolecules and reduce the immunogenicity of biomolecules. ZIF-8 has been extensively studied in the field of drug delivery due to its high porosity, ease of modification, and good biocompatibility. It has been widely used to assemble biomolecules by coprecipitation or bionic mineralization.^{13, 14} Currently, ZIF-8 is wildly used as a drug delivery system for antitumor therapy, nerve injury treatment, and poststroke nerve injury treatment.

Research progress of the application of TCM, TCM nanopreparation, and ZIF-8 nano-drug delivery system in the treatment of ischemic stroke were reviewed in this article to explore the clinical application value and future challenges of ZIF-8 as a nano-drug delivery system in the treatment of nerve injury after ischemic stroke.

2 NERVE DAMAGE AND TREATMENT AFTER ISCHEMIC STROKE

2.1 Causes of nerve damage after ischemic stroke

After ischemic stroke, the normal transmembrane ion gradient and balance of neuron cells were broken, which leads to a series of cell death processes such as oxidative and nitrifying stress, excitotoxicity, inflammation, and apoptosis, resulting in neuronal cells apoptosis or necrosis.^{15, 16}

2.2 Oxidative and nitrifying stress after ischemic stroke

Free radicals such as reactive oxygen species (ROS) and reactive nitrogen species may be important mediators of tissue damage in ischemic stroke. Free radicals formated by a variety of mechanisms mediated by N-methyl-D-aspartic acid receptor (NMDA) receptors after variable types of stroke injury.¹⁷ Oxidative and nitrifying stress arises when there is an excess of free radicals over antioxidant defenses.¹⁸ Excessive ROS will damage cellular macromolecules then lead to tissue destruction and cell death through DNA oxidative damage, protein damage, intracellular calcium release, lipid peroxidation, cytoskeletal structure damage, and chemotaxis. Together with the oxidative stress caused by ROS, it affects the cerebrovascular system via altering the BBB's molecular structure and the expression of key tight junction proteins, damaging the BBB's functional integrity. In addition, ROS can significantly cause DNA damage and mitochondrial enzyme inhibition; and nitric oxide (NO) can also affect cell functions by regulating metalloproteinases, cysteine proteases, and glycolytic enzymes.¹⁹

2.3 Excitatory toxicity after ischemic stroke

Excitatory toxicity is one of the molecular mechanisms of ischemic injury. After stroke, glutamate, as a neurotoxic excitatory neurotransmitter, plays a key role in ischemia through excitotoxic mechanisms, resulting neuronal dysfunction and degeneration.²⁰ Experiments have shown that Ca²⁺ is a key factor of glutamate neurotoxicity. Glutamate mainly acts through its receptors, among which the NMDA receptor is the most Ca²⁺ permeable glutamate ion receptor.²¹ Hyperactivation of NMDA receptors leads to excitotoxicity and neuronal death. Studies have shown that NMDA receptor blockers exert a neuroprotective effect by preventing Ca²⁺ from entering in vitro and vivo ischemic models.

2.4 Inflammation after ischemic stroke

After ischemic stroke, various molecules were activated and mediated the inflammatory cascade. The inflammatory process is related to several different cell types, inflammatory cytokines and cell receptors. The inflammatory response is initiated by the activation and recruitment of microglia. Then the microglia are induced to transform into phagocytes which produced various cytotoxic and/or cytoprotective substances. The original purpose of activated microglia is to protect neuronal cells, and microglia plays a neuroprotective role by releasing neurotrophic factors. However, excessive activation will produce proinflammatory cytokines in the ischemic area, such as interleukin 1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α),²² as well as other potentially cytotoxic molecules, such as prostaglandins, ROS, NO, and so forth, resulting in harmful inflammation and neuronal apoptosis.^{23, 24} In addition to microglia involved in brain inflammation, neutrophils, monocytes, astrocytes, T lymphocytes, mononuclear phagocytes, natural killer cells, polymorphonuclear leukocytes, and other peripheral cells can also secrete cytokines then participate in ischemic inflammation.^25-27

2.5 Apoptosis after ischemic stroke

Neuronal apoptosis is an important form of cell death. Two major pathways are divided, the death receptor (extrinsic) pathway, and mitochondria-dependent (intrinsic) pathway. Studies have shown that inhibited neuronal apoptosis mitigates ischemic injury.^{28, 29}

The endogenous pathway of cell apoptosis is realized on mitochondria, which is the center of energy synthesis and metabolism in the cell. While energy generation, it is also accompanied by the generation and release of ROS. When local brain tissue is ischemic, excessive production of ROS exceeds the ability of endogenous reductive substances to scavenge it. The accumulation of ROS in cells aroused oxidative stress, intracellular Ca²⁺ overload, toxins, ischemia, and hypoxia, resulting in the destruction of intracellular homeostasis, activation of the endogenous apoptosis pathway, finally induced cell apoptosis.

Ligand–receptor interaction initiating the exogenous cascade, which can induce the direct activation of caspase protein. Studies have reported that certain protective effects inhibited the activation of caspase protein on focal ischemic injury.³⁰ FASL, TNF, LT-α, LT-β, CD40L, LIGHT, RANKL, TRAIL, and other TNF families bind to TNF receptors, Fas receptors (FasR), and TRAIL receptors, leading to the activation of death receptors and causing mitochondria membrane permeability, chromatin condensation, DNA fragmentation, and ultimately cell death.³¹

2.6 Treatment of ischemic stroke

The treatment of stroke is currently focused on how to improve blood flow restoration, cerebrovascular circulation, and neuroprotection. Shorten the time from consultation to recanalization, minimize the infarct size, and restore the ischemic brain tissue were the main strategy. Commonly used treatment regimens including thrombolytic therapy, intravascular interventional therapy, antithrombotic therapy, and neuroprotective were also based on these.

2.7 Thrombolytic therapy

Tissue-type plasminogen activator therapy can effectively restore blood flow,³² while it is restricted by a narrow time window, contraindications, many complications, and a series of related risks.^{33, 34} As a result, only a small number of patients can receive thrombolytic therapy.³⁵

2.8 Intravascular interventional therapy

Endovascular treatment methods include mechanical intravascular thrombus removal and arterial thrombolysis which improved clinical outcomes in patients with stroke.^36-38 Because the therapeutic effect of arterial thrombolysis may be offset by delayed start-up time, the clinical safety and effectiveness of angioplasty remain to be determined,³⁹ mechanical intravascular thrombectomy is still the current first-line endovascular treatment commonly used means.

2.9 Antithrombotic therapy

Studies demonstrated that the risk of recurrence of ischemic stroke decreased when combined aspirin and clopidogrel therapy within 12 h of onset,⁴⁰ whereas it is not currently recommended for early anticoagulation therapy without selection.⁴¹

2.10 Neuroprotective therapy

The development and transformation of neuroprotective agents has gradually received more concentration in the therapy of ischemic stroke. Accordingly reported from domestic and foreign suggest that edaravone, a neuroprotective agent, improved the functional outcome of acute cerebral infarction. Administration of citicoline activated and improved brain metabolism and contribute to the recovery of brain function after brain injury,^{42, 43} but its efficacy needs to be further confirmed.⁴⁴

For neuroprotective agents, it is difficult to control the therapeutic time window of drug treatment, the actual concentration in the ischemic brain tissue area, and individual differences in patients, resulting in poor clinical transformation effects. Therefore, finding effective drugs for the treatment of ischemic stroke is urgently required.⁴⁵

Based on the many advantages of ZIF-8 in drug delivery, corresponding therapeutic drugs can be codelivered according to the specific causes of nerve damage to improve the neuroprotective effect after ischemic stroke. For example, codelivery of tissue plasminogen activator for thrombolytic therapy, codelivery of aspirin and clopidogrel for antithrombotic therapy, codelivery of edaravone and citicoline for neuroprotective therapy, and so forth.

3 APPLICATION OF TCM IN THE TREATMENT OF ISCHEMIC STROKE

3.1 Overview of the prevention and treatment of ischemic stroke with TCM

“Stroke disease” which is characterized by sudden fainting, crooked tongue, hemiplegia, and poor language,⁴⁶ weakness of blood circulation, and blood stasis. Clinically, TCM is used with conventional drugs for promoting blood circulation, removing blood stasis, and removing tendons and collaterals. Diagnosis and treatment of TCM has the characteristics of dynamic, syndrome differentiation and multicomponent, multitarget, and multipathway of TCM. TCM plays a major role in improving patients' neurological deficits, reducing inflammation, inhibiting cell apoptosis, and protecting nerve cells.

China National Stroke Database suggests that 70% of patients with ischemic stroke have been treated with Chinese medicine.⁴⁷ A study in China involving 48 general hospitals indicated that 4.4% of patients with acute ischemic stroke had used Chinese medicine in 3 months before admission, and about 31.46% of patients continued to use proprietary Chinese medicines for treatment after discharge. Another prospective observational study suggested that the proportion of new-onset ischemic stroke patients using Chinese medicine is as high as 83.1%, which has exceeded the use rate of antithrombotic drugs. According to a systematic review from 2015 to 2018, the combination of TCM is better than the conventional treatment of cerebral infarction in improving the neurological deficit of the patient with ischemic stroke within 2 weeks of onset.⁴⁸

3.2 Research status of TCM in the treatment of ischemic stroke

In recent years, TCM has become more and more significant in the prevention and treatment of stroke due to its multiple targets, multiple pathways, and few side effects by continuous research and practice. TCM prescriptions, injections, and single TCM or its active ingredients, extracts are widely used in the study of neuroprotection after ischemic stroke (Tables 1–3). The therapeutic effect of stroke has been improved to varying degrees in different research fields.

Table 1. Research on the application of traditional Chinese medicine prescriptions in the prevention and treatment of ischemic stroke

Chinese herbal formula	Effect evaluation
Buyang Huanwu Decoction	It can improve patients' neurological deficits and spasm symptoms.^49-53
Huangqi Guizhi Wuwu Decoction	It can improve the cerebral hemodynamics of patients, promote the recovery of nerve function, and has high safety.^54-58
Taohong Siwu Decoction	It can inhibit cell coke death, improve the level of inflammatory factors, improve nerve function damage.^59-63
Fuyuan Tongluo Decoction	It can improve limb motor function and nerve function, and can effectively reduce the sequela caused by cerebral infarction.^64-67
Huatuo Zaizao pills	It can significantly improve the neurological function, limb function, coagulation function, vascular endothelial function, and oxidative stress state of patients.^68-72
Tongxinluo capsule	It can improve patients' cerebral hemodynamics, limb movement function, blood lipid, inflammatory factors, and improve clinical efficacy.^73-77

Table 2. Study on the application of traditional Chinese medicine injections in the prevention and treatment of ischemic stroke

Traditional Chinese medicine injection	Effect evaluation
Ginkgolide injection	It can reduce the patient's inflammatory reaction, improve the patient's nerve function, and improve the ability of daily living.^78-82
Danshen injection	It can improve the nerve function of patients, reduce the level of serum inflammatory factors, and improve the safety of patients' treatment.^83-87
Danshen Ligustrazine injection	It can relieve the clinical symptoms and neurological dysfunction of patients and improve the clinical effect.^88-91
Shuxuetong injection	It can improve patient's nerve function and reduce adverse reactions.^92-96
Xueshuantong injection	It can effectively promote neurological function, reduce inflammatory response, and reduce adverse reactions.^97-101
Danhong injection	It can improve the patient's blood lipid level and brain function, with definite curative effect and high safety.^102-106
Shuxuening injection	It can significantly improve neurological impairment, cognitive function, blood glucose index and inflammatory factor levels.^107-111

Table 3. Study on the application of single Chinese medicine in the prevention and treatment of ischemic stroke

Single dose of Chinese medicine	Effect evaluation
Leech	It can improve the patient's nerve function and ability of daily living.^112-116
Salvia	It can effectively reduce edema and improve neurological function.^117-121
Puerarin lobata	It can significantly improve neurological function and has high safety.^122-124
Ginkgo	It can reduce neurological damage and affect oxidative and inflammatory responses through multiple pathways.^{88, 125-128}
Astragalus	It has obvious protective effect on cerebral ischemia injury, and can treat ischemic stroke through multicomponent, multitarget, and multipathway.^129-132
Chuanxiong	It can inhibit inflammatory response, improve cerebral ischemia–reperfusion injury, protect nerve cells.^{133, 134}
Panax notoginseng	It can improve the clinical efficacy of acute cerebral infarction and has good safety.^{135, 136}

3.3 Problems in the prevention and treatment of ischemic stroke with TCM

There is still no unified guideline for the use of TCM in therapy of stroke due to the wide range of characteristics of TCM. Whether a single-drug or a prescription for the treatment of ischemic stroke is largely dependent on the experience and subjective speculation of doctors. Therefore, the relevant molecular mechanism in the application of TCM needs further study. The working group of the Evidence-Based Practice Guidelines for Stroke with Integrated Traditional Chinese and Western Medicine believe that in the future, high-quality research should be given priority in the following areas: common clinical problems with high-level evidence; re-evaluation of classic TCM prescriptions with specific clinical positioning; whether the medicine is applicable or how to apply it to the links where the condition changes rapidly and the treatment risk is high.¹³⁷

Although obvious potential advantages of TCM in the prevention and treatment of stroke, many problems need to be solved, for example, the complicated composition of TCM compound prescriptions, and the unclear mechanism; the reasonable compatibility of TCM in the compound requires in-depth research; the long-period used cycles and low-efficiency; the recovery period and preventive treatment of stroke are prone to long-term medication and the phenomenon of ignoring the occurrence of adverse reactions; the characteristics of low solubility, poor stability, and poor targeting of TCM components limit its clinical application.

3.4 Research status of TCM nanopreparations in the treatment of ischemic stroke

To expand the clinical application of TCM, more and more new drugs and routes of administration were investigated. With the development of nanomedicine and nanotechnology, nanomedicine has gradually become a research hotspot in the treatment of various diseases due to the following unique advantages. First, nanomedicine can increase the solubility of insoluble drugs, improve stability, and extend the half-life of drugs in the body. Second, targeted modified nanomedicine can assist the drug to cross the BBR or be absorbed by specific cells (such as injured neurons), good therapeutic effect with the low dose and toxicity; finally, the drug can be controlled due to the different functional materials of nanomedicine.

Currently, liposomes, micelles, dendrimers, nanoparticles, and exosomes and other nanodrugs have been used in preclinical studies of ischemic stroke,¹³⁸ and improved the ischemic brain through different ways, for example, improving the efficacy and safety of thrombolytic drugs,^{139, 140} delivering oxygen to the ischemic brain,¹⁴¹ regulating ion imbalance and excitotoxicity,¹⁴² reducing oxidative stress, reducing cell apoptosis, regulating inflammation and immune response,¹⁴³ promoting tissue repair,¹⁴⁴ regulating a variety of abnormalities,¹⁴⁵ controlling the response and release of drugs at pathological sites.^{146, 147}

In recent years, the TCM nanopreparations produced by the combination of TCM and nanotechnology have to some extent made up for the shortcomings of TCM such as long treatment course, slow response, low solubility of TCM ingredients, poor stability, and poor targeting. It also reduces drug toxicity, side effects, and dosage. Various nanoformulations of TCM have improved the therapeutic effect of ischemic stroke to varying degrees through different routes of administration (oral, injection, nasal cavity, inner ear, skin; Table 4).

Table 4. Research on the application of traditional Chinese medicine nanopreparations in the prevention and treatment of ischemic stroke

Nanopreparations	Delivery system	Effect evaluation
Naotong nasal drops	Nasal spray microemulsion	It can effectively protect the nerve function and promote the recovery of nerve function.¹⁴⁸
Salvianolic acid B, tanshinone ⅡA	PLGA nanoparticles	It has a potential protective effect on cerebrovascular injury.¹⁴⁹
Curcumin	Solid lipid nano	It can improve the availability and brain distribution of curcumin.¹⁵⁰
Salvianolic acid B	Chitosan	It has good protective ability and can play a protective role in central nervous system diseases.¹⁵¹
Ginkgolide B	Polyethylene glycol	It can prolong the retention time of ginkgolide B in vivo and improve its bioavailability.¹⁵²
Panax notoginseng saponins	Nasal powder mist	It has an obvious protective effect, and the higher the dose, the stronger the protective effect.¹⁵³
Ganoderma triterpenes	Nanosuspension gel	It can increase skin surface bioavailability and reduce adverse drug reactions.^{154, 155}
Tanshinone IIA	Polyethylene glycol	It can interfere with the occurrence of inflammatory response after stroke.¹⁵⁶
Puerarin	Polybutylcyanoacrylate nanoparticles	It can increase the relative bioavailability of puerarin and enhance the protective effect on focal cerebral ischemia–reperfusion injury.¹⁵⁷
Ginsenoside Rg1	Polyglutamic acid nano-drug delivery system	It can cross the blood–brain barrier, promote the proliferation of blood vessels and nerve cells, reduce nerve cell apoptosis.¹⁵⁸
Valerenic acid	Polyethylene glycol–polylactic acid	It can regulate inflammation and oxidative stress, inhibit cell apoptosis, and play a neuroprotective role.¹⁵⁹

Abbreviation: PLGA, poly (lactic-co-glycolic acid).

However, there are also some problems in TCM nanopreparations, such as low drug load; low stability of the combination of nanocarriers and targeted drugs; the low tissue specificity targeted drugs; difficult to detect in vivo; the high cost of TCM nanopreparations. Therefore, overcoming the above problems is of great significance to the development of nanoformulations of TCM in the future.

3.5 Application and challenge of ZIF-8 in neuroprotection

In recent years, based on many features and advantages of ZIF-8, researchers have continuously used ZIF-8 to assemble functional proteins, enzymes, nucleic acids, viruses, and gene-edited originals for clinical anticancer treatment research,^{160, 161} all of which have improved tumor suppression effects to varying degrees. Based on ZIF-8 as a nanocarrier to cooperate with one or more conventional tumor treatment methods (such as chemotherapy, phototherapy, chemotherapeutic therapy, starvation therapy, immunotherapy).

Also based on the many characteristics and advantages of ZIF-8, many researchers have also applied ZIF-8 in the treatment of nerve injury. Li et al.¹⁶² used biomimetic mineralization to construct nanoassembly SOD@ZIF-8 for the treatment of Parkinson's disease (PD). The results showed that SOD@ZIF-8 can effectively eliminate ROS in cells and organisms by alleviating oxidative damage to achieve the therapeutic effect on PD. Qin et al.¹⁶³ prepared ZIF/Fer with ferrocene encapsulated ZIF-8 and applied it to the study of AβO detection. The dual detection technology combining optical sensing and electrochemical analysis of two sensing methods has played a synergistic effect in the qualitative and quantitative detection of AβO, suggesting that ZIF/Fer is a promising AβO in vivo monitoring and analysis platform. He et al.¹⁶⁴ designed ZIF-8-coated CeO₂ nanoparticles (CeO2@ZIF-8NPs) to enhance the catalytic and antioxidant activities of composite nanoparticles. The nanosystem can effectively inhibit middle cerebral artery occlusion mice. Lipid peroxidation in brain tissue reduces oxidative damage and apoptosis of neurons in brain tissue. CeO2@ZIF-8-attenuated injury by suppressed inflammation and immune responses via inhibiting the activation of astrocytes and the secretion of proinflammatory cytokines, thus exerting neuroprotective effects in the treatment of ischemic stroke. In situ synthesis pathway of synergistic nanotherapy combined with ZIF-8 and CeO₂ provide new ideas for the neuroprotection of ischemic stroke and reperfusion injury, prompting the use of ZIF-8. The drug-carrying system cocarrying TCM to treat nerve injury caused by ischemic stroke and reperfusion has potential application value (Figure 1).

Details are in the caption following the image — **Figure 1**
Open in figure viewer PowerPoint

Schematic diagram of ZIF-8 combined with TCM in the treatment of nerve injury caused by reperfusion of ischemic stroke. TCM, traditional Chinese medicine; ZIF-8, zeolitic imidazolate framework-8 [Color figure can be viewed at wileyonlinelibrary.com]

Although many advantages of ZIF-8 as a drug delivery system, there is insufficient evidence of clinical application. The mechanism of action is not completely clear, and there is insufficient evidence whether it can accurately treat damaged tissues and play a protective role. Because of TCM compound, many medicinal flavors, complex ingredients, and difficulty in in vivo pharmacokinetic research have led to the fact that most of the Chinese medicine nanopreparations currently studied are Chinese medicine monomers, and the research on Chinese medicine compounds and effective parts is relatively scarce. Given the diversity and complexity of nerve injury after ischemic stroke, it may be difficult to achieve the desired effect with a single agent. Therefore, the clinical application of ZIF-8 still faces many challenges, such as nanopreparation technology, TCM compound coloading technology, detection technology in vivo, targeting specificity, safety and stability, and so forth. Overcoming of the above problems is of great significance in the development of TCM nanopreparations in the future

4 CONCLUSION

Although TCM and TCM nanopreparations have made some progress in neuroprotection in stroke, there are still many problems that need to be solved urgently. For example, the animal model used in the research is restricted, and the patient's clinical classification and phenotypic mismatch. Attention should be paid to the research of multitarget brain-protective drugs, not only to protect neurons, but also to protect glial cells, blood vessels, and so forth. Although the nanoadministration route can pass through BBB, it cannot be confirmed whether it has reached the drug site. The mechanism of action of drugs in the brain is not clear. Nanodrugs are mostly in the laboratory research stage, and the effects of animal experiments and human experiments may be different, and there is still a lack of clinical data to prove that it is safe to apply in the clinic.

In view of the complexity of ischemic stroke injury, combination therapy may be more effective than a single drug. Compared with TCM monomers, compound medicines show more advantages. The synergistic effect of compound medicines through reasonable compatibility may have higher efficacy in neuroprotection after stroke. In the future, the research and development of nanopreparations of TCM can start from the compound prescriptions with less medicinal taste, clear active ingredients, significant therapeutic effects, and controllable quality, and carry them out with a nano-drug carrier system with good biocompatibility, targeting, and safetyprocess of drug delivery in the organism in the, to achieve better development in the neuroprotection of ischemic stroke.

5 ACKNOWLEDGMENTS

We gratefully acknowledge the every member of the neuromolecular biology team of Key Laboratory of Molecular Biology. It was with their concerted help that this review was created. here we would like to express our sincere thanks to them. This study was supported by grants from the National Natural Science Foundation of China (grant no. 81360199), Special Grant for Central Government Supporting Local Science and Technology Development, Science and Technology Department of Guizhou Province [grant no. (2019)4008], Science and Technology Plan Project of Guizhou Province (Basic Science and Technology Cooperation) [grant no. (2020)1Z060], the Science and Technology Fund Project of Guizhou Health and Health Commission (grant no. gzwjkj2019-1-039), and the Science and Technology Fund Project of Southwest Guizhou Autonomous Prefecture (grant no. 2019-1-10).

CONFLICT OF INTERESTS

We declare that our research was conducted by ourself without copy any papers and there is no conflict of interest.

ETHICS STATEMENT

Ethics statement is not applicable to this study.

AUTHOR CONTRIBUTIONS

Xiao-Xi Zhu and Dong-Fen Guo designed the study. Ming Chen and Xiao-Qiong An performed the experiments. Xiao-Xi Zhu drafted the manuscript. Bi Wang contributed to the analysis of data and designed the animal experiment. Wen-Feng Yu contributed to the conceptualization and methodology. All authors read and approved the final manuscript.

Open Research

DATA AVAILABILITY STATEMENT

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

REFERENCES

1Kefale B. Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;(18): 439-458.
PubMed Web of Science® Google Scholar
2Wang LD, Liu JM, Wang Y. The prevention and treatment of stroke still face huge challenges—brief report on stroke prevention and treatment in China, 2018. Chin Circ J. 2019; 34(02): 6-20.
Google Scholar
3Wu SM, Wu B. Stroke in China: advances and challenges in epidemiology, prevention, and management. Lancet Neurol. 2019; 18(4): 394-405.
10.1016/S1474-4422(18)30500-3
PubMed Web of Science® Google Scholar
4Zhang Y, Wei L, Du Y, Xie Y, Wu W, Yuan Y. Association between programed cell death-1 and CD4+ T cell alterations in different phases of ischemic stroke patients. Front Cell Neurosci. 2018; 12: 170.
10.3389/fncel.2018.00170
PubMed Web of Science® Google Scholar
5Members WG, Mozaffarian D, Benjamin EJ, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016; 133(4):e38.
PubMed Web of Science® Google Scholar
6Fukuta T, Asai T, Yanagida Y, et al. Combination therapy with liposomal neuroprotectants and tissue plasminogen activator for treatment of ischemic stroke. FASEB J. 2017; 31(5): 1879-1890.
10.1096/fj.201601209R
CAS PubMed Web of Science® Google Scholar
7Yuan J, Zhu YC, Yao M. Traditional Chinese medicine prescribed for acute stroke patients: a cross-sectional survey. Chin J Neurol. 2015; 48(4): 284-287.
Google Scholar
8 Neurology Society of Chinese Medical Association, Cerebrovascular Group of Neurology Society of Chinese Medical Association. Guidelines for the diagnosis and treatment of acute ischemic stroke in China 2014. Chin J Neurol. 2015; 48(4): 246-257.
Google Scholar
9 Chinese Society of Neurology, Chinese Stroke Society. China consensus on diagnosis and treatment of hemorrhage after acute cerebral infarction 2019. Chin J Neurol. 2019; 52(4): 252-265.
Google Scholar
10Gao Y. Interpretation of TCM Clinical Diagnosis and Treatment Guide: Encephalopathy. China Press of Traditional Chinese Medicine; 2015.
Google Scholar
11Guo ZJ, Yu GC, Yu XB, et al. Diagnostic criteria of integrated traditional Chinese and Western Medicine for cerebral infarction and cerebral hemorrhage. Chin J Integr Trad Western Med. 2006; 26(10): 948-949.
Google Scholar
12Li X, Tsibouklis J, Weng T, et al. Nano carriers for drug transport across the blood–brain barrier. J Drug Target. 2016; 25: 17-28.
10.1080/1061186X.2016.1184272
PubMed Web of Science® Google Scholar
13Phan A, Doonan CJ, Uribe-Romo FJ, Knobler CB, O'Keeffe M, Yaghi OM. Synthesis, structure, and carbon dioxide capture properties of zeolitic imidazolate frameworks. Acc Chem Res. 2010; 43(1): 58-67.
10.1021/ar900116g
CAS PubMed Web of Science® Google Scholar
14Sun Q, Bi H, Wang Z, et al. O₂-generating metal-organic framework-based hydrophobic photosensitizer delivery system for enhanced photodynamic therapy. ACS Appl Mater Interfaces. 2019; 11(40): 36347-36358.
10.1021/acsami.9b11607
CAS PubMed Web of Science® Google Scholar
15Siesjö BK. Pathophysiology treatment of focal cerebral ischemia. Part II: mechanism of damage and treatment. J Neurosurg. 1992; 77(3): 337-354.
10.3171/jns.1992.77.3.0337
CAS PubMed Web of Science® Google Scholar
16Titomanlio L, Fernández-López D, Manganozzi L, Moretti R, Vexler ZS, Gressens P. Pathophysiology and neuroprotection of global and focal perinatal brain injury: lessons from animal models. Pediatr Neurol. 2015; 52(6): 566-584.
10.1016/j.pediatrneurol.2015.01.016
PubMed Web of Science® Google Scholar
17Sugawara T, Chan PH. Reactive oxygen radicals and pathogenesis of neuronal death after cerebral ischemia. Antioxid Redox Signal. 2003; 5(5): 597-607.
10.1089/152308603770310266
CAS PubMed Web of Science® Google Scholar
18Wang A, Zhang X, Li S, et al. Oxidative lipoprotein markers predict poor functional outcome in patients with minor stroke or transient ischaemic attack. Eur J Neurol. 2019; 26(8): 1082-1090. doi:10.1111/ene.13943
10.1111/ene.13943
CAS PubMed Web of Science® Google Scholar
19Nakajima H, Kubo T, Ihara H, et al. Nuclear-translocated glyceraldehyde-3-phosphate dehydrogenase promotes Poly (ADP-ribose) polymerase-1 activation during oxidative/nitrosative stress in stroke J Biol Chem. 2015; 290(23): 14493-14503.
10.1074/jbc.M114.635607
CAS PubMed Web of Science® Google Scholar
20Mayor D, Tymianski M. Neurotransmitters in the mediation of cerebral ischemic injury. Neuropharmacology. 2017; 134: 178-188.
10.1016/j.neuropharm.2017.11.050
PubMed Web of Science® Google Scholar
21Lai TW, Zhang S, Wang YT. Excitotoxicity and stroke: identifying novel targets for neuroprotection. Prog Neurobiol. 2014; 115: 157-188.
10.1016/j.pneurobio.2013.11.006
CAS PubMed Web of Science® Google Scholar
22Zhao SC, Ma LS, Chu ZH, Xu H, Wu WQ, Liu F. Regulation of microglial activation in stroke. Chin Pharmacol J. 2017; 38(004): 445-458.
CAS Google Scholar
23Fernandes A, Miller-Fleming L, Pais TF. Microglia and inflammation: conspiracy, controversy or control? Cell Mol Life Sci. 2014; 71(20): 3969-3985.
10.1007/s00018-014-1670-8
CAS PubMed Web of Science® Google Scholar
24Guruswamy R, ElAli A. Complex roles of microglial cells in ischemic stroke pathobiology: new insights and future directions. Int J Mol Sci. 2017; 18(3): 496.
10.3390/ijms18030496
PubMed Web of Science® Google Scholar
25Kim B, Jeong HK, Kim JH, Lee SY, Jou I, Joe EH. Uridine 5'-diphosphate induces chemokine expression in microglia and astrocytes through activation of the P2Y6 receptor. J Immunol. 2011; 186(6): 3701-3709.
10.4049/jimmunol.1000212
CAS PubMed Web of Science® Google Scholar
26Fu Y, Liu Q, Anrather J, Shi FD. Immune interventions in stroke. Nat Rev Neurol. 2015; 11(9): 524-535.
10.1038/nrneurol.2015.144
CAS PubMed Web of Science® Google Scholar
27Siesjo BK. Mechanisms of ischemic brain damage. Crit Care Med. 1988; 16(10): 954-963.
10.1097/00003246-198810000-00006
CAS PubMed Web of Science® Google Scholar
28Huang WD, Liu XB. miR-134 regulates ischemia/reperfusion injury-induced neuronal cell death by regulating CREB signaling. J Mol Neurosci. 2015; 55(4): 821-829.
10.1007/s12031-014-0434-0
CAS PubMed Web of Science® Google Scholar
29Ross, Lan B. Acute ischemic stroke: imaging and intervention. JAMA. 2011; 306(19): 2160-2160.
10.1001/jama.2011.1680
CAS Google Scholar
30Li H, Colbourne F, Sun P, Zhao Z, Buchan AM, Iadecola C. Caspase inhibitors reduce neuronal injury after focal but not global cerebral ischemia in rats. Stroke. 2019; 2000(31): 176-182.
Google Scholar
31Isidro F, María PA. Signaling of cell death and cell survival following focal cerebral ischemia: life and death struggle in the penumbra. J Neuropathol Exp Neurol. 2003; 4: 329-339.
Google Scholar
32Wang P, Miao CY. NAMPT as a therapeutic target against stroke. Trends Pharmacol Sci. 2015; 36(12): 891-905.
10.1016/j.tips.2015.08.012
CAS PubMed Web of Science® Google Scholar
33Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008; 48(13): 1634-1635.
Google Scholar
34Ueno T, Nishijima H, Hikichi H, et al. Association of survival and hyperthermia after rt-PA for ischemic stroke. Acta Neurol Scand. 2018; 138(6): 574-578.
10.1111/ane.13011
CAS PubMed Web of Science® Google Scholar
35Majidi S, Leon Guerrero CR, Burger KM, Sigounas D, Olan WJ, Qureshi AI. Fixed dose IV rt-PA and clinical outcome in ischemic stroke patients with body weight >100 kg: pooled data from 3 randomized clinical trials. J Stroke Cerebrovasc Dis. 2018; 27(10): 2843-2848.
10.1016/j.jstrokecerebrovasdis.2018.06.016
PubMed Web of Science® Google Scholar
36Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016; 387(10029): 1723-1731.
10.1016/S0140-6736(16)00163-X
PubMed Web of Science® Google Scholar
37Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med. 2018; 378(1): 11-21.
10.1056/NEJMoa1706442
PubMed Web of Science® Google Scholar
38Albers GW, Marks MP, Kemp S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med. 2018; 378(8): 708-718.
10.1056/NEJMoa1713973
PubMed Web of Science® Google Scholar
39Furlan A. Intra-arterial prourokinase for acute ischemic stroke: the PROACT II study: a randomized controlled trial. JAMA. 2000; 283(21): 2103-2104.
PubMed Web of Science® Google Scholar
40Johnston SC, Easton JD, Farrant M, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med. 2018; 379(3): 215-225.
10.1056/NEJMoa1800410
CAS PubMed Web of Science® Google Scholar
41 Neurology Society of Chinese Medical Association, Cerebrovascular Group of Neurology Society of Chinese Medical Association. Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018. Chin J Neurol. 2018; 51(9): 666-682.
Google Scholar
42Wada T, Yasunaga H, Inokuchi R, et al. Effects of edaravone on early outcomes in acute ischemic stroke patients treated with recombinant tissue plasminogen activator. J Neurol Sci. 2014; 345(1-2): 106-111.
10.1016/j.jns.2014.07.018
CAS PubMed Web of Science® Google Scholar
43Overgaard K. The effects of citicoline on acute ischemic stroke: a review. J Stroke Cerebrovasc Dis. 2014; 23(7): 1764-1769.
10.1016/j.jstrokecerebrovasdis.2014.01.020
PubMed Web of Science® Google Scholar
44Meshkini A, Meshkini M, Sadeghi-Bazargani H. Citicoline for traumatic brain injury: a systematic review & meta-analysis. J Inj Violence Res. 2017; 9(1): 41-50.
PubMed Google Scholar
45Secades JJ, Alvarez-Sabín J, Castillo J, et al. Citicoline for acute ischemic stroke: a systematic review and formal meta-analysis of randomized, double-blind, and placebo-controlled trials. J Stroke Cerebrovasc Dis. 2016; 25: 1984-1996.
10.1016/j.jstrokecerebrovasdis.2016.04.010
PubMed Web of Science® Google Scholar
46Chamorro Á, Angel, Dirnagl U, Dirnagl U, Urra X, Planas AM. Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and infl ammation. Lancet Neurol. 2016; 15: 869-881.
10.1016/S1474-4422(16)00114-9
CAS PubMed Web of Science® Google Scholar
47Yang MY, Yu QL, Huang YS, Yang G. Neuroprotective effects of andrographolide derivative CX-10 in transient focal ischemia in rat: involvement of Nrf2/AE and TLR/NF-κB signaling. Pharmacol Res. 2019; 144: 227-234.
10.1016/j.phrs.2019.04.023
CAS PubMed Web of Science® Google Scholar
48Li JG, Wang LQ, Yang XY, et al. Chinese herbal medicine Dengzhan Xixin injection for acute ischemic stroke: a systematic review and meta-analysis of randomised controlled trials. Complement Ther Med. 2017; 34: 74-85.
10.1016/j.ctim.2017.08.004
PubMed Web of Science® Google Scholar
49Huang ZQ, Cao ZQ, Cui ZX. Clinical study of Buyang Huanwu Decoction on acute ischemic stroke with Qi deficiency and blood stasis syndrome. Chin J Integr Trad Western Med. 2021: 1-5.
Google Scholar
50Lu XH. To investigate the effect of Buyang Huanwu Decoction on the syndrome of Qi deficiency and blood stasis in cerebral infarction. China Pract Med. 2021; 16(05): 148-149.
Google Scholar
51Luo S, Pan FX, Yin CL. A randomized single blind controlled study of Buyang Huanwu Decoction in the treatment of limb spasm after apoplexy. World Chin Med. 2021; 16(03): 472-476.
CAS Google Scholar
52Ma JJ, Jiao LQ, Ma HY. Observation on the curative effect of Buyang Huanwu Decoction on the sequelae of senile cerebral infarction with Qi deficiency and blood stasis. Mod J Integr Trad Chin Western Med. 2020; 29(35): 3948-3951.
Google Scholar
53Chen TW. Improvement of neurologic function and daily living ability in the treatment of cerebral infarction by adding or subtracting Buyanghuanwu decoction. Inner Mongol J Trad Chin Med. 2020; 39(12): 30-31.
Google Scholar
54Feng XY, Zhang L. Effects of Huangqi Guizhi Wuwu Decoction combined with troxerutin on cerebral hemodynamics and prognosis of patients with cerebral infarction in recovery period. Acta Med Sin. 2020; 33(06): 170-173.
Google Scholar
55Fu CB. Effects of modified Huangqi Guizhi Wuwu Decoction on neurological deficit score and cerebral hemodynamics in patients with cerebral infarction of Qi deficiency and blood stasis syndrome in convalescence stage. Clin Res Pract. 2019; 4(02): 117-118.
Google Scholar
56Liu CS. Clinical effect of Huangqi Guizhi Wuwu Decoction on sequelae of cerebral infarction. Chin J Clin Rat Drug Use. 2020; 13(18): 127-129.
Google Scholar
57Tuo J, Bai T, Feng TD. Clinical Study of Huangqi Guizhi Wuwu Decoction combined with Yangxue Nao granules in treatment of cerebral infarction in convalescent period. J China Prescrip Drug. 2020; 18(08): 152-153.
Google Scholar
58Zhang HL. Effect of Huangqi Guizhi Wuwu Decoction on neurological function and motor function of patients with cerebral infarction in convalescent stage[J]. J Pract Trad Chin Intern Med. 2020; 34(02): 32-34.
Google Scholar
59Huang QX, Zhong YH. Clinical effect of Taohong Siwu Decoction on neurovascular unit of cerebral infarction. Shenzhen J Integr Trad Chin Western Med. 2018; 28(12): 49-50.
Google Scholar
60Wan KY, Li QF. Taohong Siwu Tang has effect on hippocampus and cortex in rats with cerebral ischemia-reperfusion. J New Chin Med. 2021; 53(01): 11-16.
CAS Google Scholar
61Wang MM. Effect of Taohong Siwu Decoction on cell pyrolysis in cerebral ischemia/reperfusion rats. Anhui Univ Chin Med. 2020; 3: 71. doi:10.26922/d.cnki.ganzc.2020.000120
Google Scholar
62Zhao BQ. Efficacy of Taohong Siwu Decoction combined with urokinase in treatment of acute cerebral infarction. Capital Food Med. 2020; 27(13): 191-192.
Google Scholar
63Zhang D. The influence of peach kernel and carthamus four substances decoction on inflammatory factors and neurological function of patients with ischemic stroke. Henan Trad Chin Med. 2019; 39(12): 1854-1857.
Google Scholar
64Wu Y, Zhao BD. Clinical research of cerebral infarction in acute phase with Qi deficiency and blood stasis syndrome treated with Fuyuan Tongluo Decoction. Chin J Trad Med Sci Technol. 2020; 27(4): 508-511.
CAS Google Scholar
65Wu Y, Zhao XH, Wang JY. Research of Fuyuan Tongluo Decoction on cerebral infarction (Qi deficiency and blood stasis syndrome) in recovery period. J Emerg Trad Chin Med. 2020; 29(01): 83-86.
Google Scholar
66Yuan PF, Zhao BD. Fuyuan Tongluo Decoction based on the experience of cardiopulmonary therapy for cerebral infarction. Cardiovasc Dis Electron J Integr Trad Chin Western Med. 2019; 007(030): 169-170.
Google Scholar
67Zhang SQ. Stroke Fuyuan Tongluo Decoction treated 51 cases of stroke sequelae. Trad Chin Med Res. 2009; 08: 47-48.
CAS Google Scholar
68Hu SS. Clinical study of huatuo zaizao pill in the treatment of phlegm and blood stasis in the sequela stage of ischemic apoplexy. Guangxi Univ Trad Chin Med. 2019; 3: 65. doi:10.27879/d.cnki.ggxzy.2019.000196
Google Scholar
69Lv Y, Wang LC, Huang C. Effect of Huatuo Zaizao pills on coagulation function and vascular endothelial function in patients with acute cerebral infarction after arterial thrombolysis. China Pharmaceut. 2019; 28(23): 63-65.
Google Scholar
70Peng JF, Qin HW, Sun YH. Effects of Huatuo Zaizao pill combined with cluster needling of scalp point therapy and vibration treatment on patients in convalescent patients with cerebral infarction. World J Integr Trad Western Med. 2020; 15(10): 1914-1917+1922.
Google Scholar
71Wu JZ. Observation on curative effect of combined application of huatuo zaizao pill and aspirin in preventing recurrence of cerebral infarction. J Med Front. 2018; 8(29): 334. doi:10.3969/j.issn.2095-1752.2018.29.282
Google Scholar
72Zhang Y. Clinical effect analysis of Chinese patent medicine huatuo zaizao pill in treating apoplexy. J China Prescrip Drug. 2019; 17(12): 105-106.
Google Scholar
73Bai JJ, Tian L, Zhang HL. Clinical value analysis of tongxinluo capsule in treating patients with acute cerebral infarction. Sichuan J Anatomy. 2019; 27(03): 68-69.
Google Scholar
74Chen JM, Han LY, Zhou F. Tongxinluo capsule assisted treatment improves limb motor function in cerebral infarction patients with syndrome of Qi deficiency and blood stasis and its effect on cerebral hemodynamics and level of vascular endothelial growth factor. Chin Arch Trad Chin Med. 2020; 38(06): 233-236.
CAS Google Scholar
75Chen YD, Jiang LX, Zhuo XP. Effect of Tongxinluo capsule combined with edaravone in the treatment of senile acute cerebral infarction and its effect on nerve function and blood lipid. Chin J Gerontol. 2021; 41(05): 930-933.
CAS Google Scholar
76Wu GF, Zhang L, Zhang SP. Effect of Tongxinluo capsule combined with edaravone injection on serum lipid level and inflammatory response in patients with acute cerebral infarction. Chin J Integr Med Cardio-Cerebrovasc Dis. 2021; 19(04): 662-664.
Google Scholar
77Ye C. Effect of Tongxinluo capsule adjuvant therapy on TCM syndrome score and vascular endothelial function in patients with atherosclerotic cerebral infarction. J New Chin Med. 2021; 53(06): 47-50.
CAS Google Scholar
78Li SH, Han XH, Jiang GY. Clinical effect of ginkgolide injection on acute cerebral infarction and its effect on serum inflammatory factors. Chin J Integr Med Cardio-Cerebrovasc Dis. 2020; 18(24): 4230-4232.
Google Scholar
79Meng TT, Jie XL, Li TT. Clinical efficacy and safety of ginkgolide injectionas the adjuvant treatment for acute ischemic stroke: a systematic review and meta-analysis. World Chin Med. 2020; 15: 1-15.
10.1186/s13020-019-0281-6
CAS PubMed Web of Science® Google Scholar
80Wang EC, Yang MB. Clinical effect of ginkgolide injection in the adjuvant treatment of acute cerebral infarction. Chin Foreign Med Res. 2020; 18(23): 38-40.
CAS Google Scholar
81Yuan HC. Effect of ginkgolide injection on nerve function and thrombotin platelet activating factor level in patients with acute ischemic cerebral infarction. Chin Remed Clin. 2020; 20(23): 3983-3985.
Google Scholar
82Deng HB, Wu DH, Shi HM. Observation on the curative effect of ginkgolide combined with edaravone in the treatment of acute cerebral infarction. Chin Commun Doctors. 2020; 36(25): 99-100.
Google Scholar
83Liu S, Wu JR, Zhang D. Meta-analysis on randomized controlled trials of compound Danshen injection in treatment for acute cerebral infarction. Chin J Pharmacoepidemiol. 2017; 26(07): 465-470.
Google Scholar
84Lu R, Hu L. The effects of compound Danshen injection combined with butylphthalide on neurological deficits and platelet activation status in ischemic apoplexy. Pract J Clin Med. 2020; 17(06): 179-182.
Google Scholar
85Ye Q, Zeng YH, Zhong KW. Application of the Danshen injection in treating atherosclerotic cerebral infarction during recovery period. J Clin Res Trad Chin Med. 2019; 11(2): 70-72.
Google Scholar
86Jin KY, Xu XJ, Li BL. Study of the effective constituents of Danshen Chuanxiongqin injection against hypoxic-ischemic brain injury. Chin J Mod Appl Pharm. 2020; 37(1): 1-8.
CAS Google Scholar
87Yan DF, Wang YJ. Research advances in pharmacological effect and clinical application of active ingredients of Danshen. China J Tradl Chin Med Pharm. 2021; 36(02): 659-662.
Google Scholar
88Lu Y, Li C, Chen Q, et al. Microthrombus-targeting micelles for neurovascular remodeling and enhanced microcirculatory perfusion in acute ischemic stroke. Adv Mater. 2019; 31(21):e1808361. doi:10.1002/adma.201808361
10.1002/adma.201808361
PubMed Web of Science® Google Scholar
89Gesong G. Clinical analysis of Salvia miltiorrhiza ligustrazine injection in the treatment of early acute cerebral infarction. Gems Health J. 2019; 26: 13-19.
Google Scholar
90Li L. The effect of Salvia miltiorrhiza ligustrazine injection in the clinical treatment of cerebral thrombosis. Guide China Med. 2020; 18(20): 61-62. doi:10.15912/j.cnki.gocm.2020.20.026
CAS Google Scholar
91Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke. 2019; 50(12): e344-e418.
10.1161/STR.0000000000000211
PubMed Web of Science® Google Scholar
92Dong FQ, Jiao HJ, Wang WJ. Comparison of therapeutic effects of Shuxuetong injection and Danhong injection on hemiplegia after ischemic stroke. Chin J Pract Nerv Dis. 2020; 023(006): 520-523.
Google Scholar
93Liang JY. Effect of Shuxuetong injection on therapeutic effect and MMSE and ADL score in patients with large area cerebral infarction. Strait Pharmaceut J. 2020; 032(004): 119-120.
Google Scholar
94Lv XF. Clinical efficacy and safety analysis of Shuxuetong injection in treating acute cerebral infarction. Clin J Chin Med. 2020; 12(15): 58-59.
Google Scholar
95Wang F. Butylphthalide injection combined with Shuxuetong injection in the treatment of acute cerebral infarction for 40 cases. Chin Med Mod Distance Educ China. 2019; 17(11): 119-120. doi:10.3969/j.issn.1672-2779.2019.11.046
CAS Google Scholar
96Xia Y. Clinical analysis of Shuxuetong injection combined with ozagrel sodium in the treatment of cerebral thrombosis. Clin Lab J. 2020; 009(002): 112-113.
Google Scholar
97Li FL, Li L, Wang Xin. Effect of Xueshuantong injection on acute cerebral infarction and its effect on serum hypersensitive C-reactive protein and interleukin-6. Mod Diagn Treat. 2019; 30(10): 1633-1635.
CAS Google Scholar
98Li Q. Clinical effect of rat nerve growth factor combined with Xueshuantong injection in the treatment of acute cerebral infarction and its effect on serum hs-CRP and IL-6. Med Health Care. 2019; 027(001): 92-93.
Google Scholar
99Liu WL. Clinical analysis of Xueshuantong injection in the treatment of ischemic stroke. J Med Aesthet Cosmetol. 2020; 29(13): 89.
Google Scholar
100Tang M, Yan QY, Li RY. The neuroprotective effect of Xueshuantong injection (lyophilization) on transient and permanent cerebral ischemia model in rats. Genom Appl Biol. 2020; v. 39(01): 469-475.
Google Scholar
101Wang HF. Clinical effect of rat nerve growth factor combined with Xueshuantong injection on acute cerebral infarction. Tibet Med. 2020; 41(03): 85-87.
Google Scholar
102Gui L, Zhou J, Zeng XY. Neuroprotective effect of Danhong injection on cerebral tissue of Mongolian gerbils after forebrain ischemia-reperfusion. Chin J Clin Pharmacol. 2021; 37(03): 255-257+261.
Google Scholar
103Li X. Clinical evaluation of Danhong injection combined with butylphthalide injection in the treatment of acute cerebral infarction. China Pract Med. 2021; 16(01): 137-139.
PubMed Web of Science® Google Scholar
104Liu HN. Effect of Danhong injection combined with edaravone on acute cerebral infarction and analysis of patients satisfaction. J Math Medicine. 2020; 33(10): 1547-1548.
Google Scholar
105Luo SM, Chen XH. Clinical effect of olacetam combined with Danhong injection in adjuvant treatment of acute cerebral infarction. Chin J Clin Rat Drug Use. 2021; 14(07): 54-55.
Google Scholar
106Yang MM, Zhang HL. Safety and effectiveness of Danhong injection in the treatment of acute cerebral infarction. China Health Stand Manage. 2021; 12(02): 126-128.
CAS Google Scholar
107Li M, Li KW, Cui LX. Clinical effect analysis of Shuxuening injection in treating cerebral infarction. J North Pharm. 2020; 017(002): 36-37.
CAS Google Scholar
108Xu MC, Xu JJ, Shao YM. Effect of Shuxuening injection on neurological function defect and cognitive function after acute cerebral infarction. J New Chin Med. 2021; 53(05): 63-65.
CAS Google Scholar
109Liu S, Wu JR, Zhang D, et al. Comparative efficacy of Chinese herbal injections for treating acute cerebral infarction: a network meta-analysis of randomized controlled trials. BMC Complement Altern Med. 2018; 18(1): 120. doi:10.1186/s12906-018-2178-9
10.1186/s12906-018-2178-9
PubMed Web of Science® Google Scholar
110Yang ZW, Liu J. Effect of Shuxuening injection combined with hydroclopidogrel on acute cerebral infarction. J Math Med. 2021; 34(02): 280-281.
Google Scholar
111Zhang KZ, Yang H. Clinical effect of Shuxuening injection on cerebral infarction in elderly patients with type 2 diabetes mellitus. Clin Res Pract. 2020; 5(34): 72-74.
Google Scholar
112Huang QY, Leng J, Gan QC. Application of leech and its preparation in cardiovascular and cerebrovascular diseases. Chin Tradit Patent Medicine. 2019; 41(08): 1915-1920.
Google Scholar
113Li XN, Niu P, Zeng JC. Application effect of Leech powder in the treatment of patients with cerebral infarction. China Mod Med. 2019; 026(016): 38-40.
Google Scholar
114Li XN, Yang TS, Zhou XL. Study on clinical effect of leech powder on collateral circulation compensation of cerebral infarction. China Pract Med. 2019; v.14(36): 150-152.
Google Scholar
115Ji W, Zhang Y, Luo J, Wan Y, Liu J, Ge RL. Memantine ameliorates cognitive impairment induced by exposure to chronic hypoxia environment at high altitude by inhibiting excitotoxicity. Life Sci. 2021; 270:119012. doi:10.1016/j.lfs.2020.119012
10.1016/j.lfs.2020.119012
CAS PubMed Web of Science® Google Scholar
116Wang W, Jiang B, Sun H, et al. Prevalence, incidence, and mortality of stroke in China: results from a nationwide population-based survey of 480687 adults. Circulation. 2017; 135(8): 759-771.
10.1161/CIRCULATIONAHA.116.025250
PubMed Web of Science® Google Scholar
117Zhang QY. Effect of Salvia miltiorrhiza injection on nerve function and serum inflammatory factor level in patients with acute cerebral infarction. Chron Pathematol J. 2020; 21(10): 1584-1586.
Google Scholar
118Zhang M. Clinical effect of Salvia miltiorrhizae and Ligustrazine Injection treating cerebral thrombosis. China Modern Medicine. 2020; 27(22): 79-81.
CAS Google Scholar
119Wang TT, Meng X, Xin K. Clinical study of Qufengtongluo Huoxue Decoction combined with Salvia miltiorrhiza injection in treating acute cerebral infarction. J Hubei Univ Chin Med. 2020; 22(05): 57-59.
CAS Google Scholar
120Pang HB & Li LL Clinical effects of Salvia ligustrazine injection combined with deproteinized calf serum injection in the treatment of acute cerebral infarction. Health for All; 2018. doi:10.3969/j.issn.1009-6019.2017.11.172
Google Scholar
121Liu YQ. Clinical observation of edaravone combined with injection of Salvia miltiorrhiza in the treatment of acute cerebral infarction. Guide China Med. 2020; 18(08): 75-76.
Google Scholar
122Liu YQ, Guo JH, Yang Y. The protective role of puerarin in blood-brain barrier of rat with experiment cerebral ischemia. J Brain Nerv Dis. 2020; 28(04): 218-221.
Google Scholar
123Zhu CH, Ge LM, Guo JH. Effects of puerarin on the levels of p-AMPK and Egr-1 in rats with cerebral infarction. Hebei Med J. 2020; 42(18): 2792-2795.
Google Scholar
124Luo M. Thirty-eight cases of acute cerebral infarction treated with supplemented Pueraria decontion. Henan Trad Chin Med. 2020; 40(04): 525-528.
Google Scholar
125Guo T, Wu ZY, Zhao XM. Ginkgo biloba extract promotes neuronal autophagy and improves neuroprotection in penumbra of cerebral ischemia. Chin J Cell Biol. 2021; 43(03): 552-560.
Google Scholar
126Huang XY, Li TT, Zhou L, et al. Analysis of the potential and mechanism of Ginkgo biloba in the treatment of Alzheimer's disease based on network pharmacology. Ibrain. 2021; 7(1): 21-28.
10.1002/j.2769-2795.2021.tb00060.x
PubMed Google Scholar
127Qu CH, Chen G, Liu J. Effects of edaravone combined with Ginkgo biloba extract on neurological function and inflammatory factors in patients with acute cerebral infarction. Chin J Clin Rat Drug Use. 2021; 14(03): 37-38+41.
Google Scholar
128Zhang L. Effect of Ginkgo biloba extract injection combined with ozagrel sodium on acute cerebral infarction. Chron Pathematol J. 2021; 22(05): 691-692.
Google Scholar
129Tang XS, Chen J, Zhang QH. Based on the network pharmacology mechanism to study the effect of astragalus membranaceus therapy of ischemic stroke. World Chin Med. 2020: 1-12.
PubMed Web of Science® Google Scholar
130Wang YH, Zhou WJ, Yan YC, et al. Network pharmacology study on the astragalus membranaceus in treatment of cerebral ischemic stroke. World J Integr Trad Western Med. 2020; v. 15(08): 107-113.
Google Scholar
131Zhao K, Zhao XM, Xu PP. Effects of astragalus membranaceus on neurological function of cerebral ischemia/reperfusion rats by regulating adenosine cyclophosphate pathway. Chin J Integr Med Cardio-Cerebrovasc Dis. 2020; 18(10): 1540-1542.
Google Scholar
132Zhao S, Yang GH, Wang X. Astragalus polysaccharides alleviates cerebral ischemia-reperfusion injury by inhibiting endoplasmic reticulum stress in rats: a mechanistic study. Chin J Biomed Eng. 2020; 26(04): 309-313.
Google Scholar
133Liu H. Effects of different doses of ligustrazine on the levels of CRP, Hcy, NSE and TNF-α in patients with cerebral infarction. Sichuan J Anatomy. 2020; 28(03): 139-140.
Google Scholar
134Yu ZH, Li LD. Effect of ligustrazine on the cerebral ischemia-reperfusion injury in mice. Chin J Clin Pharmacol. 2020; 36(12): 1648-1652.
Google Scholar
135Liang P The study on the effects of Panax notoginseng against cerebral ischemia-reperfusion injury based on neurovascular unit. Youjiang Medical College for Nationalities. 2020. doi:10.27908/d.cnki.gymzy.2020.000041
Google Scholar
136Liang P, Huang Q, Nong LY. Study on the changes of neurovascular unit after acute cerebral ischemia and intervention effect of Panax notoginseng. Mod Med J China. 2020; 22(05): 1-5.
Google Scholar
137Ni XJ, Chen YL, Cai YF. Evidence-based practice guideline on integrative medicine for stroke 2019. Chin J Evid Based Med. 2020; 20(08): 901-912.
Google Scholar
138Li C, Sun T, Jiang C. Recent advances in nanomedicines for the treatment of ischemic stroke. Acta Pharm Sin B. 2021; 11(7): 1767-1788.
10.1016/j.apsb.2020.11.019
CAS PubMed Web of Science® Google Scholar
139Teng Y, Jin H, Nan D, et al. Invivo evaluation of urokinase loaded hollow nanogels for sonothrombolysis on suture embolization induced acute ischemic stroke rat model. Bioact Mater. 2017; 3(1): 102-109.
10.1016/j.bioactmat.2017.08.001
PubMed Web of Science® Google Scholar
140Pawlowski CL, Li W, Sun M, et al. Platelet microparticle-inspired clot-responsive nanomedicine for targeted fibrinolysis. Biomaterials. 2017; 128: 94-108.
10.1016/j.biomaterials.2017.03.012
CAS PubMed Web of Science® Google Scholar
141Hamadate N, Yamaguchi T, Sugawara A, et al. Liposome-encapsulated hemoglobin ameliorates impairment of fear memory and hippocampal dysfunction after cerebral ischemia in rats. J Pharmacol Sci. 2010; 114(4): 409-419.
10.1254/jphs.10207FP
CAS PubMed Web of Science® Google Scholar
142Lv W, Xu J, Wang X, Li X, Xu Q, Xin H. Bioengineered boronic ester modified dextran polymer nanoparticles as reactive oxygen species responsive nanocarrier for ischemic stroke treatment. ACS Nano. 2018; 12(6): 5417-5426.
10.1021/acsnano.8b00477
CAS PubMed Web of Science® Google Scholar
143Xu G, Gu H, Hu B, et al. PEG-b-(PELG-g-PLL) nanoparticles as TNF-α nanocarriers: potential cerebral ischemia/reperfusion injury therapeutic applications. Int J Nanomed. 2017; 12: 2243-2254.
10.2147/IJN.S130842
CAS PubMed Web of Science® Google Scholar
144Yang J, Zhang X, Chen X, Wang L, Yang G. Exosome mediated delivery of miR-124 promotes neurogenesis after ischemia. Mol Ther Nucleic Acids. 2017; 7: 278-287.
10.1016/j.omtn.2017.04.010
CAS PubMed Web of Science® Google Scholar
145Feczkó T, Piiper A, Ansar S, et al. Stimulating brain recovery after stroke using theranostic albumin nanocarriers loaded with nerve growth factor in combination therapy. J Control Release. 2019; 293: 63-72.
10.1016/j.jconrel.2018.11.017
CAS PubMed Web of Science® Google Scholar
146Xin H, Katakowski M, Wang F, et al. MicroRNA cluster miR-17-92 cluster in exosomes enhance neuroplasticity and functional recovery after stroke in rats. Stroke. 2017; 48(3): 747-753. [Published correction appears in Stroke. 2017 May;48(5):e137].
10.1161/STROKEAHA.116.015204
CAS PubMed Web of Science® Google Scholar
147Xu J, Wang X, Yin H, et al. Sequentially site-specific delivery of thrombolytics and neuroprotectant for enhanced treatment of ischemic stroke. ACS Nano. 2019; 13(8): 8577-8588.
10.1021/acsnano.9b01798
CAS PubMed Web of Science® Google Scholar
148Huang YH, Zhu WF. Clinical study on the treatment of acute ischemic stroke by Naoqing nasal microemulsion spray. J Chin Med Mater. 2012; 01: 174-176.
Google Scholar
149Zhang X, Chen G, Wen L, et al. Novel multiple agents loaded PLGA nanoparticles for brain delivery via inner ear administration: in vitro and in vivo evaluation. Eur J Pharm Sci. 2013; 48(4-5): 595-603.
10.1016/j.ejps.2013.01.007
PubMed Web of Science® Google Scholar
150Ramalingam P, Ko YT. Enhanced oral delivery of curcumin from N-trimethyl chitosan surface-modified solid lipid nanoparticles: pharmacokinetic and brain distribution evaluations. Pharm Res. 2015; 32(2): 389-402.
10.1007/s11095-014-1469-1
CAS PubMed Web of Science® Google Scholar
151Liu YM, Wang XF, Wang D. Preparation of salvianolic acid B chitosan nanoparticles and their protective effects against heart ischemia/reperfusion injury in rats. J Liaoning Univ Trad Chin Med. 2016; 11: 16-20.
Google Scholar
152Martinez-Veracoechea FJ, Frenkel D. Designing super selectivity in multivalent nano-particle binding. Proc Natl Acad Sci U S A. 2011; 108(27): 10963-10968.
10.1073/pnas.1105351108
CAS PubMed Web of Science® Google Scholar
153Wu YJ, Zhu XY, Sha XY. The pharmacokinetics and pharmacodynamics of intranasal preparation of Panax notoginseng saponins. Acta Pharm Sin B. 2005; 04: 89-93.
Google Scholar
154Sheng CY, Shen BD, Xu PH. Preparation and in vitro transdermal diffusion characteristics of nanosuspension-based gel of triterpenoids isolated from Ganoderma lucidum. Chin Trad Herbal Drugs. 2014; 45(019): 2770-2775.
Google Scholar
155Shen BD, Shen CY, Xu LX. Application progress on nanosuspension based gel in transdermal drug delivery of Chinese materia medica. Chin Trad Herbal Drugs. 2017; 48(023): 5012-5018.
Google Scholar
156Wang X-Pharmacokinetics and related research progress of salvianolic acid B. Guide to a Happy Life magazine; 2017. 46, pp. 1011.
Google Scholar
157Nabavi S, Habtemariam S, Daglia M, et al. Neuroprotective effects of ginkgolide B against ischemic stroke: a review of current literature. Curr Top Med Chem. 2015; 15(21): 2222-2232.
10.2174/1568026615666150610142647
CAS PubMed Web of Science® Google Scholar
158Shen JY, Zhao ZM, Liu CL. Experimental study of ginsenoside Rg1 nanometer drug delivery system coupled with OX26 monoclonal antibody to promote angiogenesis and neurogenesis after cerebral infarction. J Med Postgrad. 2018; 31(04): 68-73.
Google Scholar
159Liu YW. Study on the mechanism of valerenoic acid co-loading dCas9 VP64 mRNA and its Sg RNA nanoparticles on Alzheimer's disease. 2019. Changchun University of Chinese Medicine. doi:10.26980/d.cnki.gcczc.2019.000022
Google Scholar
160Chen TT, Yi JT, Zhao YY, Chu X. Biomineralized metal-organic framework nanoparticles enable intracellular delivery and endo-lysosomal release of native active proteins [J]. J Am Chem Soc. 2018; 140(31): 9912-9920.
10.1021/jacs.8b04457
CAS PubMed Web of Science® Google Scholar
161Chen WH, Vázquez-González M, Zoabi A, Abu-Reziq R, Willner I. Biocatalytic cascades driven by enzymes encapsulated in metal–organic framework nanoparticles[J]. Nat Catal. 2018; 1(9): 689-695.
10.1038/s41929-018-0117-2
CAS Web of Science® Google Scholar
162Li Q. Enzyme assembly mediated by metal-organic frameworks and the application in biodiesel preparation and Parkinson's disease treatment. 2020. Jilin University. doi:10.27162/d.cnki.gjlin.2020.000134
Google Scholar
163Qin J, Cho M, Lee Y. Ferrocene-encapsulated Zn zeolitic imidazole framework (ZIF-8) for optical and electrochemical sensing of amyloid-β oligomers and for the early diagnosis of Alzheimer's disease. ACS Appl Mater Interfaces. 2019; 11(12): 11743-11748.
10.1021/acsami.8b21425
CAS PubMed Web of Science® Google Scholar
164He L, Huang G, Liu H, Sang C, Liu X, Chen T. Highly bioactive zeolitic imidazolate framework-8-capped nanotherapeutics for efficient reversal of reperfusion-induced injury in ischemic stroke. Sci Adv. 2020; 6:eaay9751.
10.1126/sciadv.aay9751
CAS PubMed Web of Science® Google Scholar

Volume7, Issue4

Winter 2021

Pages 337-350

Application value and challenge of traditional Chinese medicine carried by ZIF-8 in the therapy of ischemic stroke

Abstract

1 INTRODUCTION

2 NERVE DAMAGE AND TREATMENT AFTER ISCHEMIC STROKE

2.1 Causes of nerve damage after ischemic stroke

2.2 Oxidative and nitrifying stress after ischemic stroke